Millipore Sigma Vibrant Logo
Attention: We have moved. EMD Millipore products are no longer available for purchase on emdmillipore.com.Learn More

505991 Flumazenil - CAS 78755-81-4 - Calbiochem

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
78755-81-4C₁₅H₁₄FN₃O₃

Products

Catalog NumberPackaging Qty/Pack
5.05991.0001 Glass bottle 10 mg
Description
OverviewA competitive blocker of benzodiazepine activation of inhibitory GABAergic synpases (ID50 = 200 µg/kg/i.p). Binds to the benzodiazepine site of GABAA receptors. Enhances GABAA-receptor mediated currents and antagonizes the enhancing effects of benzodiapine agonist flurazepam. Exhibits fast association and dissociation from the benzodiazepine binding site. Permeates the blood brain barrier, however, the level of uptake may depend on efflux effects of p-glycogprotein transporter.
Catalogue Number505991
Brand Family Calbiochem®
SynonymsGABAA Receptor Antagonist, Flumazenil, Ro 15-1788
References
ReferencesFroklage, F.E., et al. 2012. EJNMMI Research. 2, 12.
Li, J., et al. 2006. Neuropharmacol. 51, 168.
Weiss, M., et al. 2002. Neurochem. Res. 27, 1605.
Atack, J., et al. 1999. Neuropsychopharmacol. 20, 255.
Votey, S.R., et al. 1991. Ann. Emerg. Med. 20, 181.
Product Information
CAS number78755-81-4
FormWhite solid
Hill FormulaC₁₅H₁₄FN₃O₃
Chemical formulaC₁₅H₁₄FN₃O₃
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetGABAA
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalog Number GTIN
5.05991.0001 04055977262629

Documentation

Flumazenil - CAS 78755-81-4 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Froklage, F.E., et al. 2012. EJNMMI Research. 2, 12.
Li, J., et al. 2006. Neuropharmacol. 51, 168.
Weiss, M., et al. 2002. Neurochem. Res. 27, 1605.
Atack, J., et al. 1999. Neuropsychopharmacol. 20, 255.
Votey, S.R., et al. 1991. Ann. Emerg. Med. 20, 181.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-September-2013 JSW
SynonymsGABAA Receptor Antagonist, Flumazenil, Ro 15-1788
DescriptionA competitive blocker of benzodiazepine activation of inhibitory GABAergic synpases (ID50 = 200 mg/kg/i.p). Binds to the benzodiazepine site of GABAA receptors. Enhances GABAA-receptor mediated currents and antagonizes the enhancing effects of benzodiapine agonist flurazepam. Exhibits fast association and dissociation from the benzodiazepine binding site. Permeates the blood brain barrier, however, the level of uptake may depend on efflux effects of p-glycogprotein transporter.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number78755-81-4
Chemical formulaC₁₅H₁₄FN₃O₃
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (25 mM). Slight warming is required for complete solubilization.
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesFroklage, F.E., et al. 2012. EJNMMI Research. 2, 12.
Li, J., et al. 2006. Neuropharmacol. 51, 168.
Weiss, M., et al. 2002. Neurochem. Res. 27, 1605.
Atack, J., et al. 1999. Neuropsychopharmacol. 20, 255.
Votey, S.R., et al. 1991. Ann. Emerg. Med. 20, 181.